Merck Change in Accounts Receivable 2010-2025 | MRK
Merck annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Merck change in accounts receivable for the quarter ending June 30, 2025 was $0M, a 0% increase year-over-year.
- Merck change in accounts receivable for the twelve months ending June 30, 2025 was $-0.244B, a 78.75% decline year-over-year.
- Merck annual change in accounts receivable for 2024 was $-0.244B, a 78.75% decline from 2023.
- Merck annual change in accounts receivable for 2023 was $-1.148B, a 78.26% increase from 2022.
- Merck annual change in accounts receivable for 2022 was $-0.644B, a 68.32% decline from 2021.
Merck Annual Change in Accounts Receivable
(Millions of US $) |
| 2024 |
$-244 |
| 2023 |
$-1,148 |
| 2022 |
$-644 |
| 2021 |
$-2,033 |
| 2020 |
$-1,002 |
| 2019 |
$92 |
| 2018 |
$-418 |
| 2017 |
$297 |
| 2016 |
$-619 |
| 2015 |
$-480 |
| 2014 |
$-554 |
| 2013 |
$436 |
| 2012 |
$349 |
| 2011 |
$-1,168 |
| 2010 |
$-1,089 |
| 2009 |
$165 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$213.086B |
$64.168B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
